These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 26480871)

  • 1. Re-engineering a neuroprotective, clinical drug as a procognitive agent with high in vivo potency and with GABAA potentiating activity for use in dementia.
    Luo J; Lee SH; VandeVrede L; Qin Z; Piyankarage S; Tavassoli E; Asghodom RT; Ben Aissa M; Fà M; Arancio O; Yue L; Pepperberg DR; Thatcher GR
    BMC Neurosci; 2015 Oct; 16():67. PubMed ID: 26480871
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A multifunctional therapeutic approach to disease modification in multiple familial mouse models and a novel sporadic model of Alzheimer's disease.
    Luo J; Lee SH; VandeVrede L; Qin Z; Ben Aissa M; Larson J; Teich AF; Arancio O; D'Souza Y; Elharram A; Koster K; Tai LM; LaDu MJ; Bennett BM; Thatcher GR
    Mol Neurodegener; 2016 Apr; 11():35. PubMed ID: 27129593
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cassia obtusifolia seed ameliorates amyloid β-induced synaptic dysfunction through anti-inflammatory and Akt/GSK-3β pathways.
    Yi JH; Park HJ; Lee S; Jung JW; Kim BC; Lee YC; Ryu JH; Kim DH
    J Ethnopharmacol; 2016 Feb; 178():50-7. PubMed ID: 26674159
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Icariin, a phosphodiesterase-5 inhibitor, improves learning and memory in APP/PS1 transgenic mice by stimulation of NO/cGMP signalling.
    Jin F; Gong QH; Xu YS; Wang LN; Jin H; Li F; Li LS; Ma YM; Shi JS
    Int J Neuropsychopharmacol; 2014 Jun; 17(6):871-81. PubMed ID: 24513083
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liraglutide can reverse memory impairment, synaptic loss and reduce plaque load in aged APP/PS1 mice, a model of Alzheimer's disease.
    McClean PL; Hölscher C
    Neuropharmacology; 2014 Jan; 76 Pt A():57-67. PubMed ID: 23973293
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lixisenatide, a drug developed to treat type 2 diabetes, shows neuroprotective effects in a mouse model of Alzheimer's disease.
    McClean PL; Hölscher C
    Neuropharmacology; 2014 Nov; 86():241-58. PubMed ID: 25107586
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel analogues of chlormethiazole are neuroprotective in four cellular models of neurodegeneration by a mechanism with variable dependence on GABA(A) receptor potentiation.
    Vandevrede L; Tavassoli E; Luo J; Qin Z; Yue L; Pepperberg DR; Thatcher GR
    Br J Pharmacol; 2014 Jan; 171(2):389-402. PubMed ID: 24116891
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacological Rescue of Long-Term Potentiation in Alzheimer Diseased Synapses.
    Prieto GA; Trieu BH; Dang CT; Bilousova T; Gylys KH; Berchtold NC; Lynch G; Cotman CW
    J Neurosci; 2017 Feb; 37(5):1197-1212. PubMed ID: 27986924
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-diabetes drug pioglitazone ameliorates synaptic defects in AD transgenic mice by inhibiting cyclin-dependent kinase5 activity.
    Chen J; Li S; Sun W; Li J
    PLoS One; 2015; 10(4):e0123864. PubMed ID: 25875370
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic significance of NR2B-containing NMDA receptors and mGluR5 metabotropic glutamate receptors in mediating the synaptotoxic effects of β-amyloid oligomers on long-term potentiation (LTP) in murine hippocampal slices.
    Rammes G; Hasenjäger A; Sroka-Saidi K; Deussing JM; Parsons CG
    Neuropharmacology; 2011 May; 60(6):982-90. PubMed ID: 21310164
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Probucol, a lipid-lowering drug, prevents cognitive and hippocampal synaptic impairments induced by amyloid β peptide in mice.
    Santos DB; Peres KC; Ribeiro RP; Colle D; dos Santos AA; Moreira EL; Souza DO; Figueiredo CP; Farina M
    Exp Neurol; 2012 Feb; 233(2):767-75. PubMed ID: 22173317
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A critical role of NO/cGMP/PKG dependent pathway in hippocampal post-ischemic LTP: modulation by zonisamide.
    Costa C; Tozzi A; Siliquini S; Galletti F; Cardaioli G; Tantucci M; Pisani F; Calabresi P
    Neurobiol Dis; 2011 Nov; 44(2):185-91. PubMed ID: 21749921
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuritin can normalize neural deficits of Alzheimer's disease.
    An K; Jung JH; Jeong AY; Kim HG; Jung SY; Lee K; Kim HJ; Kim SJ; Jeong TY; Son Y; Kim HS; Kim JH
    Cell Death Dis; 2014 Nov; 5(11):e1523. PubMed ID: 25393479
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lixisenatide rescues spatial memory and synaptic plasticity from amyloid β protein-induced impairments in rats.
    Cai HY; Hölscher C; Yue XH; Zhang SX; Wang XH; Qiao F; Yang W; Qi JS
    Neuroscience; 2014 Sep; 277():6-13. PubMed ID: 24583037
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of the neurotrophic agent T-817MA on oligomeric amyloid-β-induced deficits in long-term potentiation in the hippocampal CA1 subfield.
    Takamura Y; Ono K; Matsumoto J; Yamada M; Nishijo H
    Neurobiol Aging; 2014 Mar; 35(3):532-6. PubMed ID: 24112791
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Furoxans (1,2,5-oxadiazole-N-oxides) as novel NO mimetic neuroprotective and procognitive agents.
    Schiefer IT; VandeVrede L; Fa' M; Arancio O; Thatcher GR
    J Med Chem; 2012 Apr; 55(7):3076-87. PubMed ID: 22429006
    [TBL] [Abstract][Full Text] [Related]  

  • 17. AF710B, a Novel M1/σ1 Agonist with Therapeutic Efficacy in Animal Models of Alzheimer’s Disease.
    Fisher A; Bezprozvanny I; Wu L; Ryskamp DA; Bar-Ner N; Natan N; Brandeis R; Elkon H; Nahum V; Gershonov E; LaFerla FM; Medeiros R
    Neurodegener Dis; 2016; 16(1-2):95-110. PubMed ID: 26606130
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neuroprotective potential of high-dose biotin.
    McCarty MF; DiNicolantonio JJ
    Med Hypotheses; 2017 Nov; 109():145-149. PubMed ID: 29150274
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Age-related synaptic dysfunction in Tg2576 mice starts as a failure in early long-term potentiation which develops into a full abolishment of late long-term potentiation.
    Fernández-Fernández D; Dorner-Ciossek C; Kroker KS; Rosenbrock H
    J Neurosci Res; 2016 Mar; 94(3):266-81. PubMed ID: 26629777
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Involvement of the nitric oxide pathway in synaptic dysfunction following amyloid elevation in Alzheimer's disease.
    Puzzo D; Palmeri A; Arancio O
    Rev Neurosci; 2006; 17(5):497-523. PubMed ID: 17180876
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.